NEW YORK, NY, March 26, 2026 /24-7PressRelease/ -- Creative Diagnostics, a reagent supplier and developer focused on biologics quality control, has announced the launch of its innovative SpeX™ Earthworm Microsomes. This new addition to the subcellular fraction product line provides researchers with a cost-effective, high-performance alternative to traditional mammalian models for drug metabolism, pharmacokinetics, and environmental risk assessment.

Earthworms are a valuable, multifunctional resource in drug development. They have evolved sophisticated defense mechanisms against microbial infections, and the bioactive agents in earthworm extracts (EEs) demonstrate potent antibacterial, antifungal, and antiviral properties in both in vitro and in vivo studies. EE alleviates inflammation triggered by infections and effectively mitigates pain. Recent research has also revealed that EE can lower blood glucose levels.

Earthworms possess unique and irreplaceable value in pharmaceutical research, particularly excelling in three key domains: 1) serving as distinctive pharmacological models and screening tools for studying specific drug metabolism pathways, 2) functioning as critical biological indicators for environmental risk assessment, and 3) serving as a rich source of bioactive substances and lead compounds. Earthworm microsomes, prepared via homogenization centrifugation, are rich in key drug-metabolizing enzymes, including cytochrome P450 (CYP450), as well as transport enzymes, such as glutathione S-transferases. These enzymes are crucial for the "detoxification" or "activation" of exogenous compounds.

Earthworms' multiple unique characteristics bridge the gap between laboratory research and natural environments. They help researchers assess the impact of drugs on ecosystems and serve as a low-cost screening tool for early-stage drug discovery. Furthermore, research indicates that earthworms may harbor compounds with therapeutic potential for major diseases. Recognizing the unique value of earthworms, Creative Diagnostics has developed SpeXᵀᴹ Earthworm Microsomes, an innovative and economical 3Rs-compliant model that offers an efficient solution for drug screening.

Creative Diagnostics' SpeX® Earthworm Microsome model is a crucial for studying drug metabolism and the environmental fate of pharmaceuticals within soil biocommunity systems. This model assists researchers in evaluating the environmental risks and ecotoxicity of pharmaceuticals. Additionally, the metabolic mechanisms of earthworms and mammalian intestines are highly similar (both are rich in CYP450 enzymes and transferases), making this novel product an ideal complementary model for mammalian drug metabolism research. It effectively simulates the first-pass metabolism of orally administered drugs and provides a vital tool for bioavailability studies. Most significantly, as a unique non-mammalian model, earthworm microsomes open new avenues for exploring novel metabolic pathways and drive innovation in drug metabolism research.

Creative Diagnostics is committed to delivering cutting-edge solutions that optimize researchers' drug development workflows. The SpeX® Earthworm Microsome Model aims to provide unique insights, elevate the standard of bioavailability studies, and accelerate research progress with precision.

For more information regarding the SpeX™ Earthworm Microsomes or to request a quote, please visit https://qbd.creative-diagnostics.com/spex-earthworm-microsomes.html.

About Creative Diagnostics

Creative Diagnostics is a global leader in the development and manufacturing of innovative tools and reagents for bioprocess impurity analysis. The company offers a comprehensive portfolio of solutions to support researchers in the quality control of biologics and provides biopharmaceutical quality, purity and safety assays, analytical methods and applications for the biotechnology and biopharmaceutical industries.

# # #